Incyte’s Opzelura Treatment for Skin Disease: A Mixed Bag of Results

Incyte Corp has made headlines recently with the release of mixed data from late-stage studies of its Opzelura treatment for skin disease characterized by itchy firm lumps, known as prurigo nodularis. The company’s stock has a target price set by TD Cowen at $88, with a Buy rating, but analysts are now left wondering about the potential approval of Opzelura.

The mixed results come from two separate Phase 3 studies, TRuE-PN1 and TRuE-PN2. While the full data from TRuE-PN1 showed that the treatment met all primary and key secondary endpoints, the top-line data from TRuE-PN2 revealed that the primary endpoint did not reach statistical significance. This discrepancy has left analysts uncertain about the treatment’s prospects.

Despite the mixed results, Opzelura has shown superiority in efficacy in two prurigo nodularis studies. This suggests that the treatment may still have a place in the market, but its approval is far from guaranteed. As the regulatory landscape continues to evolve, Incyte will need to navigate the complexities of the approval process to bring Opzelura to market.

Key Takeaways:

• Incyte’s Opzelura treatment has shown mixed results in late-stage studies
• The treatment met all primary and key secondary endpoints in one study, but failed to reach statistical significance in another
• Opzelura has shown superiority in efficacy in two prurigo nodularis studies
• Analysts are uncertain about the treatment’s prospects for approval
• Incyte’s stock has a target price set by TD Cowen at $88, with a Buy rating